CAR-T Therapies: 10 Years On and the Future of CAR-T

19 Jan 2023
Modalities and Indications Track
Adaptive Biotechnologies

11:00am Chair Introduction

Steve Kanner, Chief Scientific Officer, Caribou Biosciences


11:05am Presentation: The Improbable Development of CAR T Therapy

  • Advances in the understanding of basic immunology have ushered in two major approaches for cancer therapy over the past 10 years: checkpoint therapy and CAR T
  • The emergence of synthetic biology approaches for cellular engineering provides a broadly expanded set of tools for programming immune cells for enhanced function
  • Barriers to therapy of solid tumors will be discussed

Carl H. June, Director of the Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania 


11:20am Presentation: How Can We Better Track CAR-T Therapy Inside of Patients?

    • Cell therapies have the ability to migrate, expand, and persist throughout the body
    • Current methods to track cell therapies rely on legacy approaches originally designed for gene therapy
    • Immune cells have natural barcodes that can be leveraged to track cell therapies throughout the body at the individual clone level with superior specificity and sensitivity

Alex Dahmani, Director of Business Development, Adaptive Biotechnologies


11:35am Presentation: Modularisation of CAR Immune Cell Therapies That Adapt to a Changing Oncology Landscape

  • OmniCAR is a covalent universal immune receptor system agnostic to cell type and targeting ligand type
  • Modularity enables multi-valent and/or sequential arming

Dan Shelly, Vice President of Business Development and Alliances, Prescient Therapeutics


11:50am Presentation: 5 Years into the Commercialization of CAR T’s  – Are We Meeting Patient Needs?

  • Discuss whether the currently approved CAR T’s are reaching the patients that they were designed to benefit
  • Discuss the current challenges for patients in receiving approved CAR T cell therapies and how we can improve

Jennifer Chow, Chief Executive Officer, Chimeric Therapeutics


12:05pm Closing Panel with Q&A

With all session participants joined by: 

Sujay Kango, Chief Executive Officer, Tmunity


Alex Dahmani
Director of Business Development
Adaptive Biotechnologies
Carl H. June
Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine
University of Pennsylvania
Dan Shelly
Vice President of Business Development and Alliances
Prescient Therapeutics
Steve Kanner
Chief Scientific Officer
Caribou Biosciences
Sujay Kango
Chief Executive Officer
Jennifer Chow
Chief Executive Officer & Managing Director
Chimeric Therapeutics